Janux shares up 90% as T cell en­gager shows ear­ly signs of PSA re­sponse in prostate can­cer

Janux Ther­a­peu­tics’ share price has rock­et­ed on the back of Phase Ia dose-es­ca­la­tion da­ta for its tu­mor-ac­ti­vat­ed T cell en­gager in ad­vanced or metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer.

The Phase Ia is test­ing the drug, JANX007, in pa­tients with a me­di­an of four or more lines of pri­or ther­a­py, per a com­pa­ny re­lease. The drug can­di­date tar­gets both prostate-spe­cif­ic mem­brane anti­gen (PS­MA) and CD3.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.